Corporate Profile for EntreMed, Inc., dated July 26, 1996.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones Dow Jones the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202] See : Finance News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0- Published Date: July 26, 1996 Company Name: EntreMed, Inc.
Address: 9610 Medical Center Drive, Suite 200
Rockville, Md. 20850
Main Telephone Number: 301/217-9858 Chief Executive Officer: Dr. John W. Holaday Investor Relations Contact: Susan J. Lewis Business number: 303/804-0494 Home number: 303/804-0493 Public Relations Contact: Susan J. Lewis Business number: 303/804-0494 Home number: 303/804-0493 Trading Symbol: NASDAQ:ENMD Industry: Biopharmaceutical, Biotechnology
Market Makers: Volpe, Welty & Co., Dillon Read & Co., Interstate
Securities, Sherwood Securities and Troster Singer
Company description: Rockville, Md.-based EntreMed, Inc. is an innovative biopharmaceutical company which develops products that address the role of blood and blood vessels Blood and Blood Vessels acidosis Medicine. a condition of the blood in which the alkali reserve is lower than normal. Also called acid intoxication, autointoxication. — acidotic, adj. in health and disease. The Company's strategy is to identify new core technologies and to acquire exclusive rights through sponsored research programs with university medical facilities, research companies and government laboratories. EntreMed anticipates commercialization of its products through strategic partnerships with major pharmaceutical companies. The Company is a leader in the field of antiangiogenesis research, which involves the stopping of blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. growth believed to be associated with a broad range of diseases. On June 12, 1996, the Company announced its IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. of 3.2 million shares of common stock, priced at $15 per share. Bristol-Myers Squibb Company (NYSE NYSE See: New York Stock Exchange :BMY BMY Bristol Myers Squibb ), one of the Company's strategic partners, agreed to purchase an additional 333,333 shares at the IPO price in a private placement at the close of the offering. EntreMed has 11,993,912 shares outstanding. Its stock trades on the Nasdaq National Market under the symbol ENMD. CONTACT: EntreMed |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion